Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Genedrive making “good progress” as revenues rise across board, Hep-C assay nears EU approval

Genedrive submitted its Genedrive HCV ID kit for CE IVD certification back in March and said today it expects to hear back in the “near future”
Genedrive's HCV ID Kit
The HCV assay provides on-the-spot results in just 90 minutes

Genedrive PLC (LON:GDR) has enjoyed a year of “good progress”, in which it saw revenues rise  as its breakthrough rapid diagnostic for Hepatitis-C moved nearer to European regulatory approval.

The molecular diagnostics specialist submitted its Genedrive HCV ID kit for CE IVD certification back in March and said today it expects to update the market on the outcome of this application in the “near future”.

Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.

READ: Genedrive -Ready to launch the first point-of-care HepC test

The receipt of CE IVD certification under the EU Medical Devices Directive would green-light the commercialisation of the product in the European Union.

Revenues grow, health financial position

It wasn’t just a year of operational progress though, Genedrive finished the year in a solid financial position after it saw revenues grow across the board.

For the 12 months to 30 June 2017, the AIM-quoted firm reported group revenues of £5.8mln, comfortably ahead of the £5.1mln it posted last year.

Of that, £2.6mln came from diagnostic-related revenues (2016: £1.9mln), while services revenues accounted for £3.2mln (2016: £3.1mln).

The company closed the period with cash of £5.1mln (2016: £1.1mln), thanks to the £6.5mln it raised this time last year.

It burnt through £0.6mln in the second half of the year, with cash flows helped out by a £0.8mln tax credit.

Possible sale of services division

Although the services business continues to make a positive contribution to cash flows, Genedrive doesn’t deem it a core part of the company going forward and is looking at the possibility of offloading it.

None of the offers to acquire the division have been acceptable yet, Genedrive said, adding that it is also exploring other ways which would allow the business to best contribute to the group.  

‘Significant’ few months coming up

“We have continued the good progress made in the first six months of the calendar year and continue to work towards realising the proven potential of the Genedrive platform across several value creating opportunities,” said chief executive David Budd.

“The forthcoming months will be significant for the Company as there are a number of near-term milestones expected to be achieved, in particular for the Genedrive HCV ID kit.”

Full-year results for the 12 months ended 30 June are expected to be published in October.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
car-t cells definition
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use